Key result
NOACs match VKAs for thromboembolism prevention during cardioversion while reducing major bleeding.
Why the study?
The comparative efficacy and safety of contemporary anticoagulation strategies for electrical cardioversion of AF had not been integrated within a single quantitative framework combining randomized and real-world evidence.
Does NOAC-based anticoagulation reduce stroke or systemic embolism and major bleeding compared with VKA-based anticoagulation in adults undergoing electrical cardioversion for atrial fibrillation or atrial flutter?
Meta-Analysis (n=93,271)
Yes
Does NOAC-based anticoagulation reduce stroke or systemic embolism and major bleeding compared with VKA-based anticoagulation in adults undergoing electrical cardioversion for atrial fibrillation or atrial flutter?
Answers are grounded in this paper and cite their sources.
This comprehensive meta-analysis of 93,271 patients/procedures demonstrates that NOACs provide thromboembolic protection at least equivalent to VKAs with lower observational major bleeding during electrical cardioversion of AF, while omitting periprocedural anticoagulation triples thromboembolic risk.
Introduction: Electrical cardioversion (ECV) is the most effective method for restoring sinus rhythm in atrial fibrillation (AF), but it transiently amplifies the risk of thromboembolism through atrial stunning and a post-conversion prothrombotic state. Several anticoagulation strategies coexist in contemporary practice: dose-adjusted vitamin K antagonists (VKA) with or without heparin bridging, non-vitamin K antagonist oral anticoagulants (NOAC), imaging-guided early versus conventional delayed cardioversion, and, in acute-onset AF, cardioversion without periprocedural anticoagulation. Their comparative efficacy and safety have not been integrated within a single quantitative framework that combines randomized and real-world evidence. We therefore aimed to compare these strategies with respect to thromboembolism, bleeding, mortality, and pre-cardioversion left atrial thrombus. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. PubMed, Europe PMC, Google Scholar, Semantic Scholar, and ClinicalTrials.gov were searched for reports published between January 2011 and October 2026. Randomized controlled trials (RCTs), RCT-derived cardioversion analyses, comparative cohort studies, and case series of adults undergoing ECV for AF or atrial flutter were eligible. Risk of bias was assessed with RoB 2, ROBINS-I, and the JBI checklist for case series. Risk ratios (RR) were pooled with DerSimonian–Laird random-effects models, complemented by Mantel–Haenszel fixed-effect, Peto, and Hartung–Knapp–Sidik–Jonkman (HKSJ) analyses with prediction intervals; adjusted estimates were pooled by generic inverse variance and single-arm incidences by the Freeman–Tukey transformation. Certainty of evidence was graded with GRADE. Results: Thirty-five studies (42 reports) were included: 8 RCTs or RCT-derived analyses, 20 comparative cohorts, and 7 case series, encompassing 93,271 patients or cardioversion procedures. Compared with VKA, NOAC-based anticoagulation yielded a similar risk of stroke or systemic embolism (RR 0.90; 95% CI 0.65–1.26; 18 studies; I² = 0%), with a numerically lower estimate in randomized evidence (RR 0.60; 95% CI 0.27–1.35). Major bleeding was reduced (RR 0.66; 95% CI 0.45–0.96; 17 studies; absolute difference -1.6 per 1,000 cardioversions), a benefit driven by observational cohorts and attenuated in randomized trials (RR 0.91; 95% CI 0.49–1.70). In dedicated cardioversion RCTs, the trial-defined efficacy composite was lower with NOAC (RR 0.43; 95% CI 0.21–0.87), and ischaemic stroke was reduced (RR 0.10; 95% CI 0.01–0.77; 2 RCTs). All-cause mortality did not differ (RR 0.74; 95% CI 0.32–1.68). Treatment effects were consistent across early/transoesophageal echocardiography (TEE)-guided and delayed strategies (P for interaction = 0.80), individual NOACs (P = 0.38), and prior anticoagulant exposure (P = 0.55). Imaging-guided/early cardioversion was not associated with different thromboembolic risk compared with conventional delayed cardioversion (RR 0.88; 95% CI 0.41–1.90). Periprocedural oral anticoagulation, compared with none, reduced thromboembolism by 63% (RR 0.37; 95% CI 0.28–0.49; 7 studies; I² = 0%). Pooled post-cardioversion thromboembolic incidence was 0.17% with NOAC, 0.32% with VKA, and 0.45% without anticoagulation. Certainty of evidence ranged from low to very low. Discussion: NOAC-based strategies provide thromboembolic protection at least equivalent to well-managed VKA during ECV, with a favourable but design-dependent bleeding signal and practical advantages that permit earlier cardioversion. The protective effect of periprocedural anticoagulation is large and consistent, including in acute-onset AF, whereas the choice between imaging-guided early and conventional delayed timing does not appear to modify thromboembolic risk when therapeutic anticoagulation is ensured. Conclusion: Uninterrupted therapeutic anticoagulation, preferably with a NOAC, should accompany every electrical cardioversion of AF irrespective of AF duration in patients with thromboembolic risk factors, either for at least 3 weeks before cardioversion or with imaging exclusion of left atrial thrombus, and for at least 4 weeks afterwards. Adequately powered randomized trials of strategy timing, reduced-dose regimens, and acute-onset AF are still required.
No takes yet. Share an insight, caveat, or question.
Mujidiatama et al. (2026) conducted a meta-analysis in Atrial fibrillation or atrial flutter undergoing electrical cardioversion (n=93,271). Non-vitamin K antagonist oral anticoagulants (NOAC: dabigatran, rivaroxaban, apixaban, edoxaban) vs. Vitamin K antagonists (VKA: warfarin, acenocoumarol, phenprocoumon) with or without heparin bridging was evaluated on Stroke or systemic embolism (primary efficacy) (RR 0.90, 95% CI 0.65-1.26). NOAC-based anticoagulation yielded a similar risk of stroke or systemic embolism and lower major bleeding compared with VKA during ECV.
Synapse has enriched 10 related papers. Consider them for comparative context: